Abstract：
BACKGROUND: Preservation of organ function and viability is a crucial factor for survival in cardiogenic shock (CS) patients. There is not information enough on cytoprotective substances that may delay organs damage in CS. We hypothesize that cytidine-5-diphosphocholine (CDP-choline) can act as a cytoprotective pharmacological measure that diminishes the target organ damage. So, we aimed to perform a review of works carried out in our institution to evaluate the effect of therapeutic cytoprotection of the CDP-choline.
CONCLUSIONS: CDP-choline is an intermediate metabolite in the synthesis of phosphatidylcholine. It is also a useful drug for the treatment of acute ischaemic stroke, traumatic brain injury, and neurodegenerative diseases and has shown an excellent pharmacological safety profile as well. We review our institution\'s work and described the cytoprotective effects of CDP-choline in experimental models of heart, liver, and kidney acute damage, where this compound was shown to diminish reperfusion-induced ventricular arrhythmias, oxidative stress, apoptotic cell death, inflammation, lactic acid levels and to preserve mitochondrial function.
CONCLUSIONS: We propose that additional research is needed to evaluate the impact of cytoprotective therapy adjuvant to mitigate target organ damage in patients with CS.
CONCLUSIONS: CDP-choline is an intermediate metabolite in the synthesis of phosphatidylcholine. It is also a useful drug for the treatment of acute ischaemic stroke, traumatic brain injury, and neurodegenerative diseases and has shown an excellent pharmacological safety profile as well. We review our institution\'s work and described the cytoprotective effects of CDP-choline in experimental models of heart, liver, and kidney acute damage, where this compound was shown to diminish reperfusion-induced ventricular arrhythmias, oxidative stress, apoptotic cell death, inflammation, lactic acid levels and to preserve mitochondrial function.
CONCLUSIONS: We propose that additional research is needed to evaluate the impact of cytoprotective therapy adjuvant to mitigate target organ damage in patients with CS.
摘要：
背景：保持器官功能和活力是心源性休克（CS）患者生存的关键因素。关于可能延迟CS器官损伤的细胞保护物质的信息不足。我们假设胞苷-5-二磷酸胆碱（CDP-胆碱）可以作为一种细胞保护药理措施，减少靶器官的损害。所以,我们旨在对我们机构开展的工作进行回顾,以评估CDP-胆碱的治疗性细胞保护作用.
结论：CDP-胆碱是磷脂酰胆碱合成的中间代谢产物。它也是治疗急性缺血性中风的有用药物，创伤性脑损伤,和神经退行性疾病，并已显示出良好的药理安全性以及。我们回顾了我们机构的工作，并描述了CDP-胆碱在心脏实验模型中的细胞保护作用，肝脏,和肾脏急性损伤，这种化合物被证明可以减少再灌注引起的室性心律失常，氧化应激，凋亡性细胞死亡，炎症,乳酸水平和保持线粒体功能。
结论：我们建议需要更多的研究来评估细胞保护性治疗辅助治疗对减轻CS患者靶器官损伤的影响。
结论：CDP-胆碱是磷脂酰胆碱合成的中间代谢产物。它也是治疗急性缺血性中风的有用药物，创伤性脑损伤,和神经退行性疾病，并已显示出良好的药理安全性以及。我们回顾了我们机构的工作，并描述了CDP-胆碱在心脏实验模型中的细胞保护作用，肝脏,和肾脏急性损伤，这种化合物被证明可以减少再灌注引起的室性心律失常，氧化应激，凋亡性细胞死亡，炎症,乳酸水平和保持线粒体功能。
结论：我们建议需要更多的研究来评估细胞保护性治疗辅助治疗对减轻CS患者靶器官损伤的影响。
